London HIV Consortium issues new guidelines for ARV prescribing (2011)
1 April 2011. Related: Antiretrovirals, Guidelines.
Antiretrovirals
EMA issue restricted indication for d4T (stavudine)
1 April 2011. Related: Antiretrovirals.
Changes to starting dose of saquinavir in naive patients
1 April 2011. Related: Antiretrovirals.
FDA approve nevirapine XR
1 April 2011. Related: Antiretrovirals.
Lopinavir/r oral solution
1 April 2011. Related: Antiretrovirals.
Atazanavir use during pregnancy
1 April 2011. Related: Antiretrovirals, Pregnancy.
Nelfinavir interaction with warfarin
1 April 2011. Related: Antiretrovirals.
Lopinavir/ritonavir: women versus men
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Quality of life in the GRACE study
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Antiretroviral pharmacokinetics in women with undetectable viral load
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Lipodystrophy and metabolic complications.
The impact of antiretroviral treatment on fertility intentions in South Africa
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
US adult treatment guidelines updated January 2011
1 February 2011. Related: Antiretrovirals, Guidelines.
FDA safety updates to antiretroviral labels
1 February 2011. Related: Antiretrovirals.
Darunavir once-daily indication in treatment experienced adults
1 February 2011. Related: Antiretrovirals.
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
1 December 2010. Related: Conference reports, Antiretrovirals.
Efavirenz versus nevirapine based first linetreatment in a South African cohort
1 December 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
1 December 2010. Related: Conference reports, Antiretrovirals.
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
1 December 2010. Related: Conference reports, Antiretrovirals, Guidelines.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Adding maraviroc does not boost CD4s inrandomised trial
1 December 2010. Related: Conference reports, Antiretrovirals.
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
1 December 2010. Related: Conference reports, Antiretrovirals.
Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350
1 December 2010. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study
1 December 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 December 2010. Related: Antiretrovirals, Side effects.
Update to US saquinavir label
1 December 2010. Related: Antiretrovirals, Side effects.
Raltegravir pharmacokinetics inpregnancy
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Low birth weight associated with HAART in pregnancy in Zambia
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Novel mutations and shifting susceptibility to darunavir and tipranavir
1 October 2010. Related: Conference reports, Antiretrovirals, Drug resistance.
Four-drug single-pill antiretroviral equivalent to Atripla at 48 weeks
1 October 2010. Related: Conference reports, Antiretrovirals.
High rates of bone loss and progression with HIV in longitudinal study
1 October 2010. Related: Conference reports, Antiretrovirals, Side effects.
Spray-dried nanoparticle formulation of efavirenz
1 October 2010. Related: Conference reports, Antiretrovirals.
Switching boosted-PIs to raltegravir
1 October 2010. Related: Conference reports, Antiretrovirals, Treatment strategies.
Early infant diagnosis
1 October 2010. Related: Conference reports, Antiretrovirals, Paediatric care, Diagnostics.
Efavirenz-based regimens among womenof reproductive age receiving ART in Johannesburg
1 October 2010. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
START study given green light for full study
1 October 2010. Related: Antiretrovirals.
Saquinavir prolongation of QT interval: Rocheissue Dear Doctor letter
1 October 2010. Related: Antiretrovirals.
Development of chronic kidney disease and antiretroviral use in EuroSIDA cohortsince 2004
1 October 2010. Related: Antiretrovirals, Side effects.
Rilpivirine (TMC-278) vs efavirenz in treatment-naive patients: phase 3 results
26 August 2010. Related: Conference reports, Antiretrovirals.
Once-daily nevirapine extended release (XR) is non-inferior to current formulation
26 August 2010. Related: Conference reports, Antiretrovirals.
GSK572 (dolutegravir): second-generation integrase inhibitor
26 August 2010. Related: Conference reports, Antiretrovirals.
TBR-652: early results for CCR5 inhibitor
26 August 2010. Related: Conference reports, Antiretrovirals.
Atazanavir/r plus maraviroc or tenofovir/FTC in treatment-naive patients
26 August 2010. Related: Conference reports, Antiretrovirals.
Unboosted twice-daily atazanavir plus raltegravir
26 August 2010. Related: Conference reports, Antiretrovirals.
CASCADE analysis of when to start treatment
26 August 2010. Related: Conference reports, Antiretrovirals.
Impact of antiretroviral PMTCT prophylaxis regimens on subsequent maternal disease progression in Kesho Bora
26 August 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Birth outcomes with antiretroviral exposure
26 August 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
No difference in outcomes for children initiating treatment with a protease inhibitor or an NNRTI nor with viral load switching strategies in PENPACT-1
26 August 2010. Related: Conference reports, Antiretrovirals, Paediatric care.
Tablets more acceptable than syrups in the ARROW trial
26 August 2010. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Paediatric formulation of TMC 278
26 August 2010. Related: Conference reports, Antiretrovirals, Paediatric care.
FDA safety updates to antiretroviral labels
26 August 2010. Related: Antiretrovirals.
Raltegravir approved inScotland
26 August 2010. Related: Antiretrovirals, Treatment access.
Atazanavir/r approved in Europefor children aged 6 to 18 years
26 August 2010. Related: Antiretrovirals, Treatment access, Paediatric care.
FDA finally approves 4th generation HIV Ag/Ab test in the US
26 August 2010. Related: Antiretrovirals, Treatment access, Pregnancy, Paediatric care, Diagnostics.
Antiretroviral pipeline 2010
1 July 2010. Related: Pipeline report, Antiretrovirals.
HIV diagnostics pipeline
1 July 2010. Related: Pipeline report, Antiretrovirals, Diagnostics.
START study launched and endorsed by broad community support: over 140 community organisations sign letter to US guideline panel
1 June 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 June 2010. Related: Antiretrovirals.
Development of apricitabine halted without finding backer for Phase 3
1 June 2010. Related: Antiretrovirals.
Treatment reduces infections by over 90%: a theme that is here to stay
2 April 2010. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients
2 April 2010. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.
Pipeline compounds and new approaches to treatment
2 April 2010. Related: Conference reports, Antiretrovirals.